Ritlecitinib approved for alopecia areata, largest JAK inhibitor trial confirms 80% regrowthStemson Therapeutics completes first human follicle cloning safety studyExosome therapy: 18-month follow-up data shows durable results in 62% of patientsCRISPR-based AGA treatment enters Phase I, first gene-editing approach for hair lossClascoterone Phase 3 results: topical antiandrogen matches finasteride without systemic effectsOral minoxidil 1.25mg outperforms topical 5% in new randomised trialWnt pathway activator SM04554 fails Phase III, researchers identify whyScalp microbiome transplant: first human results show promise for seborrheic alopeciaPRP meta-analysis 2025: 28 trials, 1,400 patients, here are the real numbersDutasteride mesotherapy significantly outperforms oral dutasteride in crown hair densityRitlecitinib approved for alopecia areata, largest JAK inhibitor trial confirms 80% regrowthStemson Therapeutics completes first human follicle cloning safety studyExosome therapy: 18-month follow-up data shows durable results in 62% of patientsCRISPR-based AGA treatment enters Phase I, first gene-editing approach for hair lossClascoterone Phase 3 results: topical antiandrogen matches finasteride without systemic effectsOral minoxidil 1.25mg outperforms topical 5% in new randomised trialWnt pathway activator SM04554 fails Phase III, researchers identify whyScalp microbiome transplant: first human results show promise for seborrheic alopeciaPRP meta-analysis 2025: 28 trials, 1,400 patients, here are the real numbersDutasteride mesotherapy significantly outperforms oral dutasteride in crown hair density

The science of hair loss, decoded.

Daily research coverage tracking every credible path to a complete cure by 2030.

Cure deadline

1323d09h23m31s
Advertisement
May 16, 2026

One breakthrough a day, every day

Don’t miss the cure announcement.

Join 47,200+ people tracking every study, every trial, every step toward 2030.

Free forever. No spam. Unsubscribe anytime.